AI Article Synopsis
- Gene and cell therapies are being developed for serious illnesses, with a few approved treatments, but their high costs create access issues.
- Most clinical trials focus on high-income countries, leaving low- and middle-income nations at a disadvantage.
- The review highlights the progress and challenges of gene and cell therapies in Brazil, South Africa, and India, incorporating insights from ASGCT virtual discussions in those regions.
Article Abstract
Gene and cell therapies for a variety of life-limiting illnesses are under investigation, and a small number of commercial products have successfully obtained regulatory approval. The cost of treatment is high, and clinical studies evaluating safety and efficacy are performed predominately in high-income countries. We reviewed the current status of gene and cell therapies in low- and middle-income countries and highlighted the need and current barriers to access. The state of product development in Brazil, South Africa, and India is discussed, including lessons learned from American Society of Gene and Cell Therapy (ASGCT)-sponsored virtual symposia in each of these countries.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9171243 | PMC |
| http://dx.doi.org/10.1016/j.ymthe.2022.04.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!